Roth Capital Cuts Price Target on Apricus Biosciences (APRI) to $3 Following 2Q15
Tweet Send to a Friend
Roth Capital maintained a Buy rating on Apricus Biosciences (NASDAQ: APRI), and cut the price target to $3.00 (from $4.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
